NCT06294912View on ClinicalTrials.gov

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 18, 2024

Primary Completion Date

January 6, 2025

Study Completion Date

January 6, 2025

Conditions
Malaria
Interventions
OTHER

Plasmodium falciparum

Parasite inoculation administered by intravenous (IV) infusion as the challenge agent

DRUG

MK-7602

Capsules to be administered orally.

DRUG

Artemether/lumefantrine

Tablets to be administered orally as definitive antimalarial treatment.

DRUG

Primaquine

Tablets to be administered orally as definitive antimalarial treatment.

DRUG

Artesunate

Intravenous (IV) infusion to be administered as definitive antimalarial treatment.

DRUG

Atovaquone/proguanil

Tablets to be administered orally as definitive antimalarial treatment.

Trial Locations (1)

4101

USC Clinical Trials Brisbane (South Bank) ( Site 0001), South Brisbane

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06294912 - A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) | Biotech Hunter | Biotech Hunter